Tal Veig,
Tel Aviv University,
Israel

T CELL ENGINEERING USING V(D)J RECOMBINATION ALLOWS TUMOR GROWTH INHIBITION IN MICE 

🕛 12:40 – 12:45  

Alon Richter,
Tel Aviv University,
Israel

FcγRI-DRIVEN T CELL-MEDIATED ADCC AS A STRATEGY FOR TREATING SOLID TUMORS 

🕛 12:45 – 12:50 

Lisa Gregor,
LMU Clinic,
Germany

PROSTANOID-INSENSITIVE CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS MEDIATE THERAPEUTIC EFFICACY IN SOLID CANCER MODELS 

🕛 12:50 – 12:55 

Anaïs Jiménez-Reinoso,
12 de Octubre University Hospital,
Spain

TUMOR-INFILTRATING LYMPHOCYTES SECRETING T CELL-ENGAGING ANTIBODIES INDUCE REGRESSION OF PATIENT-DERIVED LUNG CANCER XENOGRAFTS 

🕛 12:55 – 13:00 

Franziska Füchsl,
Technical University Munich,
Germany

FINE-TUNING SIGNAL-STRENGTH IN T CELL-BASED ADOPTIVE CELLULAR ANTI-CANCER THERAPIES: TRANSIENT LOW-DOSE MEK-INHIBITION FOR POTENTIATING ENGINEERED T CELLS 

🕛 13:00 – 13:05 

Michela Consonni,
IRCCS San Raffaele Scientific Institute,
Italy

OPTIMIZING ADOPTIVE IMMUNOTHERAPY OF LEUKEMIA WITH CD1C-REDIRECTED T AND INKT CELLS

🕛 13:05 – 13:10 

Tiffany Que,
UNIL-CHUV,
Switzerland

POTENCY TUNED NOVEL CD70 CAR-T CELLS WITH A COMPUTATIONALLY DESIGNED CD27:CD70 BINDING INTERFACE FOR ACUTE MYELOID LEUKEMIA

🕛 13:10 – 13:15 

Jule Müschen,
Technical University Munich,
Germany

T CELL STIMULATION AND PIFITHRIN-ALPHA CONTROL DNA DELETION SIZES AND ANEUPLOIDY IN CRISPR-EDITED HUMAN T CELLS 

🕛 13:15 – 13:20 

Adrian Straub,
Technical University Munich,
Germany

UNRAVELING T-CELL-RECEPTOR (TCR) SPECIFICITY: TCR LANGUAGE MODELS TO PREDICT AND DESIGN TCR:EPITOPE INTERACTIONS

🕛 13:20 – 13:25 

Ata Ul Wakeel Ahmad,
MDC Berlin,
Germany

ENGINEERING B CELLS THROUGH THE INTEGRATION OF HIV-RECEPTOR EXONS

🕛 13:25– 13:30